

I. AMENDMENTS

IN THE CLAIMS

Cancel claims 2, 10, and 17-19 without prejudice to renewal.

Please enter the amendments to claims 1 and 26, as shown below.

1. (Currently Amended) A method of reducing goblet cell hyperplasia in an airway of an individual, comprising:

administering to a patient suffering from airway hypersecretion of mucus due to airway goblet cell hyperplasia an epidermal growth factor receptor (EGF-R) antagonist that binds the EGF-R to a patient suffering from airway hypersecretion of mucus due to airway goblet cell hyperplasia in an amount effective to reduce goblet cell hyperplasia, wherein the EGF-R antagonist is a tyrosine kinase inhibitor selective for EGF-R.

2. (Canceled)

3. (Original) The method of claim 2, wherein said antagonist is BIBX1522.

4.-9. (Withdrawn)

10. (Canceled)

11. (Withdrawn)

12. (Original) The method of claim 1, wherein the antagonist is administered by injection.

13. (Original) The method of claim 12, wherein the antagonist is administered intravenously with a carrier in the form of normal saline solution.

14. (Original) The method of claim 1, wherein the antagonist is administered by inhalation.

15. (Original) The method of claim 1, wherein the antagonist is administered by liposome

delivery.

16. (Original) The method of claim 15, wherein said liposome is sterically stabilized and administered intravenously.

17.-19. (Canceled)

B | 20.-25. (Withdrawn)

26. (Currently Amended) A method of treating nasal polyps, comprising administering to a patient suffering from nasal polyps an epidermal growth factor receptor (EGF-R) antagonist that binds an EGF-R ~~to a patient suffering nasal polyps~~ in an amount effective to reduce goblet cell hyperplasia, wherein the EGF-R antagonist is a tyrosine kinase inhibitor selective for EGF-R.
